Hong Kong
Search
Sign In
Change Password
Points
Sign Out
Urology
Top Medical News
Testicular cancer survivors (TCSs) demonstrate similar health-related quality of life (HRQoL) to that of the general population at a median of 28 years since treatment initiation, reports a study.
The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.
In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).
A 68-year-old male patient presented with bone pain at multiple sites in November 2022. He did not have any other symptoms. He had hypertension and type 2 diabetes mellitus (T2DM), which were well controlled with amlodipine besylate 5 mg BID and metformin 1 g BID, respectively. He was generally well and had a baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0.
An 80-year-old male presented with rectal bleeding and elevated prostate-specific antigen (PSA; 100 ng/mL) in October 2021. Biopsy of rectal tissue showed adenocarcinoma of the prostate. Molecular testing found that the disease was microsatellite instability (MSI)–stable, with no targetable mutations; tumour mutational burden was zero. His Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was 1.
Use of a standardized and manualized intervention in a primary care setting results in a sustained decrease in lower urinary tract symptoms (LUTS) in men compared with usual care, results of the TRIUMPH study have shown.
Treatment with flexible ureteroscopy (FE) results in a significantly higher stone-free rate than shock wave lithotripsy (SWL) in children with renal stones, reports a study. No difference is seen in complication rate or fluoroscopy exposure time between groups, but operative times and hospital stay are longer with FU.
Special Reports
A 68-year-old male patient presented with bone pain at multiple sites in November 2022. He did not have any other symptoms. He had hypertension and type 2 diabetes mellitus (T2DM), which were well controlled with amlodipine besylate 5 mg BID and metformin 1 g BID, respectively. He was generally well and had a baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0.
An 80-year-old male presented with rectal bleeding and elevated prostate-specific antigen (PSA; 100 ng/mL) in October 2021. Biopsy of rectal tissue showed adenocarcinoma of the prostate. Molecular testing found that the disease was microsatellite instability (MSI)–stable, with no targetable mutations; tumour mutational burden was zero. His Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was 1.
A 69-year-old male presented with lower limb weakness and urinary retention in February 2018 and was admitted to the orthopaedic ward. He had a history of hypertension and hyperlipidaemia, which were controlled with lisinopril and simvastatin, respectively.
Current standard first-line treatment options for metastatic castration-resistant prostate cancer (mCRPC) provide modest survival benefits. At the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2023), Professor Noel Clarke of The Christie at Salford Royal NHS Foundation Trust in Manchester, UK, presented final prespecified overall survival (OS) analysis results of the phase III PROpel study, which showed a sustained trend for OS improvement associated with olaparib in combination with abiraterone vs standard-of-care (SoC) abiraterone alone in men with mCRPC.
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.
A 76-year-old patient was referred to a urologist with the finding of raised prostate-specific antigen (PSA; 10.5 µg/L) in 2007. Prostate biopsy confirmed the diagnosis of prostate cancer with a Gleason score of 8 (4+4).
Conference Reports
The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.
In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).
The prostate-specific membrane antigen (PSMA)–targeted radioligand, lutetium-177 (177Lu)–PSMA-617, improves radiographic progression-free survival (rPFS) vs androgen receptor pathway inhibitor (ARPI) switch and has a favourable safety profile in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on one prior second-generation ARPI, results of the phase III PSMAfore trial have shown.
In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).
Whatever choice of therapy men with localized prostate cancer may have initially— surgery, radiation, or active monitoring — they would likely have a good 15-year outcome as shown in the ProtecT* trial.
Men who are considering vasectomy can rest easy knowing that the procedure has no harmful effect on their sexual health, as suggested in a study presented at EAU 2023.
In patients with locally advanced or metastatic urothelial cancer patients receiving atezolizumab treatment, immune-related adverse events (AEs) were associated with improved survival outcomes, according to an analysis of individual participant data from the IMvigor210 and IMvigor211 studies.